26 results
8-K
EX-99.2
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
period and 3 in placebo period) Most common AEs by MedDRA system organ class: - GI: nausea, diarrhea - Injury & procedural complications: procedural
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business … greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise
DRS
98ob3cewx9oe uc6c4j
20 Oct 22
Draft registration statement
12:00am
10-K
3rh10sro088
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
xk2i1vdqu9ba1ik vp
10 Jan 22
Regulation FD Disclosure
7:01am
10-Q
xa3v8jlz xop
17 Nov 21
Quarterly report
5:15pm
424B4
q76kjgsotp0kfyt
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
EX-10.18
uzz68 clahv
19 Jul 21
IPO registration
7:02am
S-1
EX-10.4
egqtom9 kp
19 Jul 21
IPO registration
7:02am
S-1
EX-10.6
cpp3z ibt
19 Jul 21
IPO registration
7:02am
S-1
EX-10.15
eomh9v9smozcvf44t2
19 Jul 21
IPO registration
7:02am
S-1
EX-10.17
m5ayo0tl
19 Jul 21
IPO registration
7:02am
S-1
pwi4w6j7eq mxbuai1
19 Jul 21
IPO registration
7:02am